Neurological sequelae of cancer immunotherapies and targeted therapies
- 1 December 2016
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 17 (12) , e529-e541
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Pfizer
This publication has 66 references indexed in Scilit:
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene TherapyJournal of Immunotherapy, 2013
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLBlood, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanomaCancer Management and Research, 2012
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cellsBlood, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Paraneoplastic syndromes of the CNSThe Lancet Neurology, 2008
- Inflammation and cancerNature, 2002